Table 2.

Vorinostat in clinical trials.

Drug	Conditions	Status	NCT number	Phases
Vorinostat	Glioblastoma, gliosarcoma, brain tumor	Completed	NCT00641706	Phase 2
Vorinostat	Ovarian cancer, primary peritoneal cavity cancer	Completed	NCT00132067	Phase 2
Vorinostat	Lymphoma	Completed	NCT00771472	Phase 1
Vorinostat	Leukemia, myelodysplastic syndromes	Completed	NCT00305773	Phase 2
Vorinostat	Advanced cancer relapsed and refractory	Completed	NCT00632931	Phase 1
Vorinostat	Carcinoma, non‐small‐cell lung	Terminated with result	NCT00251589	Phase 1, 2
Vorinostat	Glioblastoma, gliosarcoma, brain tumor	Completed	NCT01647100	Phase 2
Vorinostat	Mesothelioma|lung cancer	Completed	NCT00128102	Phase 3
Vorinostat	Breast cancer	Completed	NCT00132002	Phase 2
Vorinostat	Lung cancer	Completed	NCT00138203	Phase 2
Vorinostat	Brain and central nervous system tumors	Completed	NCT00238303	Phase 2
Vorinostat	Myelodysplastic syndromes	Completed	NCT00776503	Phase 1, 2
Vorinostat	Cancer	Completed	NCT00045006	Phase 1
Vorinostat	Head and neck cancer	Completed	NCT00134043	Phase 2
Vorinostat	Pelvic cancer|radiotherapy	Completed	NCT00455351	Phase 1
Vorinostat	Hematologic and solid cancer	Terminated	NCT01116154	Phase 1
Vorinostat	Tumors	Completed	NCT00127127	Phase 1
Vorinostat	Brain, CNS, intestine tumors, lymphoma	Completed	NCT00499811	Phase 1
Vorinostat	MDS, blood and bone marrow disease	Terminated	NCT00486720	Phase 2
Vorinostat	Advanced cancer	Completed	NCT00907738	Phase 2
Vorinostat	Lymphoma	Completed	NCT00127140	Phase 1
Vorinostat	Colorectal cancer	Completed	NCT00336141	Phase 1
Vorinostat	Hematologia and solid cancer	Completed	NCT00005634	Phase 1
Vorinostat	Kidney cancer	Completed	NCT00354250	Phase 2